|
 
Last update: |
 |
|
|
29-Nov-2023
|
 |
|
|
Arch Hellen Med, 40(6), November-December 2023, 754-764 REVIEW The contribution of new biomarkers in the prevention and treatment of diabetic ulcer I.A. Anastasiou, K. Tentolouris, I. Eleftheriadou, O. Kosta, A. Kontogiannatou, Α. Katsaouni, A. Koulouri, C. Siafarikas |
Diabetic foot ulcers concern one of the main chronic serious complications of diabetes mellitus that do not follow the normal healing process. In daily clinical practice, clinical criteria are used for risk stratification and ulcer prevention in people with diabetes. The use of new biomarkers may contribute to the prevention of ulcers with consequent reductions in hospitalizations, amputations, disability, costs and mortality. In addition to the most extensively studied and used inflammatory biomarkers, such as C-reactive protein (CRP) and procalcitonin (PCT), there are other potential biomarkers such as pentraxin-3 (PTX-3), interleukins (IL), and tumor necrosis factor-α (TNF-α). Recent advances in molecular biology, genomics, transcriptomics, proteomics, metabolomics and microbiome have led to the identification of biomolecules that can be used as potential biomarkers for diabetic ulcer risk stratification and in the future to generalize their use in clinical practice.
Key words: Biomarkers, Biomolecules, C-reactive protein, Diabetes mellitus, Diabetic foot ulcer, Genomics, Metabolomics and microbiome, Proteomics, Transcriptomics.
